Fairvalue-Calculator Fairvalue-Calculator
EN DE

GENINUS Inc (389030) Fair Value & Analysis

Healthcare · KR · Market cap 111B KRW

Price2,265 KRW
Fair Value417.49 KRW
Upside-81.6%
Quality95/100
Evidence: Low Range 313.12 KRW – 521.86 KRW

Fair value as of: Jun 24, 2026

Analysis

GENINUS Inc (389030) currently trades at 2,265 KRW, while our model-based Fair Value estimate is 417.49 KRW — implying the stock looks roughly 81.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of genome analysis solutions in South Korea, the United States, and Asia. It offers tarhet and biomarker discovery; AI digital pathology; single cell analysis; and spatial and in-situ transcriptomics services; and SPACEINSIGHT, a cutting-edge cloud based integrated analysis platform. It serves hospitals, pharmaceutical companies, and researchers. The company was founded in 2018 and is headquartered in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is GENINUS Inc (389030) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 417.49 KRW versus a price of 2,265 KRW — about −82% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 389030?
Our 21-model fair value for GENINUS Inc is 417.49 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 2,265 KRW.
What is the quality score of 389030?
GENINUS Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.